Bio­con on­col­o­gy spin­out Bicara se­cures its sec­ond nine-fig­ure fi­nanc­ing of the year

Bicara Ther­a­peu­tics, an im­munother­a­py start­up out of In­di­an bio­phar­ma gi­ant Bio­con, an­nounced a $165 mil­lion Se­ries C on Tues­day morn­ing.

The round fea­tured some blue-chip names that are rem­i­nis­cent of crossover rounds from years past, in­clud­ing TPG, Braid­well, Deer­field Man­age­ment and oth­ers. But with the biotech IPO mar­ket cur­rent­ly de­pressed, Bicara will keep its op­tions open as it has suf­fi­cient fund­ing to start an ex­pect­ed piv­otal tri­al “to­ward the end of next year,” CEO Claire Mazum­dar told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER